BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20155608)

  • 1. A trial to reduce hepatitis C seroincidence in drug users.
    Stein MD; Herman DS; Anderson BJ
    J Addict Dis; 2009 Oct; 28(4):389-98. PubMed ID: 20155608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users.
    Miller CL; Johnston C; Spittal PM; Li K; Laliberté N; Montaner JS; Schechter MT
    Hepatology; 2002 Sep; 36(3):737-42. PubMed ID: 12198668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion.
    Hagan H; Thiede H; Des Jarlais DC
    Epidemiology; 2004 Sep; 15(5):543-9. PubMed ID: 15308953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes.
    Vallejo F; Barrio G; Brugal MT; Pulido J; Toro C; Sordo L; Espelt A; Bravo MJ;
    J Epidemiol Community Health; 2015 Jun; 69(6):599-603. PubMed ID: 25870164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCV seroconversion among never-injecting heroin users at baseline: no predictors identified other than starting injection.
    Bravo MJ; Vallejo F; Barrio G; Brugal MT; Molist G; Pulido J; Sordo L; de la Fuente L;
    Int J Drug Policy; 2012 Sep; 23(5):415-9. PubMed ID: 22421554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: Assessing barriers to hepatitis C prevention.
    Puzhko S; Roy É; Jutras-Aswad D; Artenie AA; Fortier E; Zang G; Bruneau J
    Int J Drug Policy; 2017 Sep; 47():61-68. PubMed ID: 28666636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of a reduction in heroin availability on patterns of drug use, risk behaviour and incidence of hepatitis C virus infection in injecting drug users in New South Wales, Australia.
    Maher L; Li J; Jalaludin B; Wand H; Jayasuriya R; Dixon D; Kaldor JM
    Drug Alcohol Depend; 2007 Jul; 89(2-3):244-50. PubMed ID: 17289299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working?
    Taylor A; Goldberg D; Hutchinson S; Cameron S; Gore SM; McMenamin J; Green S; Pithie A; Fox R
    J Infect; 2000 Mar; 40(2):176-83. PubMed ID: 10841096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection.
    Patrick DM; Tyndall MW; Cornelisse PG; Li K; Sherlock CH; Rekart ML; Strathdee SA; Currie SL; Schechter MT; O'Shaughnessy MV
    CMAJ; 2001 Oct; 165(7):889-95. PubMed ID: 11599327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C Virus seroconversion among persons who inject drugs in relation to primary care physician visiting: The potential role of primary healthcare in a combined approach to Hepatitis C prevention.
    Artenie AA; Roy É; Zang G; Jutras-Aswad D; Bamvita JM; Puzhko S; Daniel M; Bruneau J
    Int J Drug Policy; 2015 Oct; 26(10):970-5. PubMed ID: 26005038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.
    Tsui JI; Evans JL; Lum PJ; Hahn JA; Page K
    JAMA Intern Med; 2014 Dec; 174(12):1974-81. PubMed ID: 25347412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada.
    Jacka B; Roy É; Høj S; Minoyan N; Artenie AA; Zang G; Jutras-Aswad D; Bruneau J
    J Viral Hepat; 2019 Dec; 26(12):1413-1422. PubMed ID: 31433888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the feasibility of hepatitis C virus vaccine trials: results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study.
    White B; Madden A; Prins M; Hellard M; Wand H; Dore GJ; Page K; Maher L
    Vaccine; 2014 Sep; 32(42):5460-7. PubMed ID: 25131726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users.
    Bruneau J; Roy E; Arruda N; Zang G; Jutras-Aswad D
    Addiction; 2012 Jul; 107(7):1318-27. PubMed ID: 22248184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus seroconversion among young injection drug users: relationships and risks.
    Hahn JA; Page-Shafer K; Lum PJ; Bourgois P; Stein E; Evans JL; Busch MP; Tobler LH; Phelps B; Moss AR
    J Infect Dis; 2002 Dec; 186(11):1558-64. PubMed ID: 12447730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004.
    Holtzman D; Barry V; Ouellet LJ; Des Jarlais DC; Vlahov D; Golub ET; Hudson SM; Garfein RS
    Prev Med; 2009 Aug; 49(1):68-73. PubMed ID: 19410600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus infection: prevalence, predictor variables and prevention opportunities among drug users in Italy.
    Quaglio GL; Lugoboni F; Pajusco B; Sarti M; Talamini G; Mezzelani P; Des Jarlais DC;
    J Viral Hepat; 2003 Sep; 10(5):394-400. PubMed ID: 12969192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence.
    Rezza G; Sagliocca L; Zaccarelli M; Nespoli M; Siconolfi M; Baldassarre C
    Scand J Infect Dis; 1996; 28(1):27-9. PubMed ID: 9122628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk behaviors after hepatitis C virus seroconversion in young injection drug users in San Francisco.
    Tsui JI; Vittinghoff E; Hahn JA; Evans JL; Davidson PJ; Page K
    Drug Alcohol Depend; 2009 Nov; 105(1-2):160-3. PubMed ID: 19647375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brief counseling for reducing sexual risk and bacterial STIs among drug users--results from project RESPECT.
    Semaan S; Neumann MS; Hutchins K; D'Anna LH; Kamb ML;
    Drug Alcohol Depend; 2010 Jan; 106(1):7-15. PubMed ID: 19720471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.